Atropine Treatment For Myopia Is Obvious, Petitioner Tells Board

(January 11, 2022, 1:31 PM EST) -- ALEXANDRIA, Va. — In a Jan. 7 petition for inter partes review filed with the Patent Trial and Appeal Board, a clinical stage ophthalmic company seeks cancellation of various claims of...
To view the full article, register now.